Ward, Brian J., et al. “Phase 1 Trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants.” MedRxiv, Cold Spring Harbor Laboratory Press, Nov. 2020, p. 2020.11.04.20226282. www.medrxiv.org, doi:10.1101/2020.11.04.20226282.

Smith College

- RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study 
- Safety and Immunogenicity of the Ad26.COV2.S COVID-19 Vaccine Candidate: Interim Results of a Phase 1/2a, Double-blind, Randomized, Placebo-Controlled Trial
- Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial
-Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants

Biomedical Engineering for COVID-19 Articles from MedRxiv

Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., . . . Gruber, W. C. (2020). RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study. doi:10.1101/2020.08.17.20176651

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study 

Sadoff, J., Gars, M. L., Shukarev, G., Heerwegh, D., Truyers, C., Groot, A. M., . . . Schuitemaker, H. (2020). Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: Interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. MedRxiv. doi:10.1101/2020.09.23.20199604

Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial

Yan-Jun Zhang, Gang Zeng, Hong-Xing Pan, Chang-Gui Li, Biao Kan, Ya-Ling Hu, Hai-Yan Mao, Qian-Qian Xin, Kai Chu, Wei-Xiao Han, Zhen Chen, Rong Tang, Wei-Dong Yin, Xin Chen, Xue-Jie Gong, Chuan Qin, Yuan-Sheng Hu, Xiao-Yong Liu, Guo-Liang Cui, Cong-Bing Jiang, Heng-Ming Zhang, Jing-Xin Li, Min-Nan Yang, Xiao-Juan Lian, Yan Song, Jin-Xing Lu, Xiang-Xi Wang, Miao Xu, Qiang Gao, Feng-Cai Zhu
medRxiv 2020.07.31.20161216; doi: https://doi.org/10.1101/2020.07.31.20161216

Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial

Learn Before

Related